CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $43,950,005 | -12.2% | 2,736,613 | 0.0% | 1.61% | -24.0% |
| Q4 2022 | $50,080,018 | -30.7% | 2,736,613 | -25.6% | 2.11% | -29.2% |
| Q3 2022 | $72,255,000 | +5.3% | 3,678,947 | 0.0% | 2.98% | -9.9% |
| Q2 2022 | $68,612,000 | +4.1% | 3,678,947 | +22.5% | 3.31% | +25.6% |
| Q1 2022 | $65,935,000 | -22.7% | 3,003,879 | 0.0% | 2.64% | -14.8% |
| Q4 2021 | $85,340,000 | +325.0% | 3,003,879 | +214.9% | 3.10% | +295.7% |
| Q3 2021 | $20,079,000 | +4284.1% | 953,879 | +3828.7% | 0.78% | +4505.9% |
| Q2 2021 | $458,000 | – | 24,280 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |